Free Trial
Andrew Tsai

Andrew Tsai Analyst Performance

Senior Vice President at Jefferies Financial Group

Andrew Tsai is a stock analyst at Jefferies Financial Group, covering 11 publicly traded companies across a range of sectors. Over the past year, Andrew Tsai has issued 9 stock ratings, including buy and hold recommendations. While full access to Andrew Tsai's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew Tsai's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 5 Years
Buy Recommendations
81.82% 9 Buy Ratings
Companies Covered
11 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy81.8%9 ratings
Hold18.2%2 ratings
Sell0.0%0 ratings

Out of 11 total stock ratings issued by Andrew Tsai at Jefferies Financial Group, the majority (81.8%) have been Buy recommendations, followed by 18.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
90.9% of companies on NASDAQ
10 companies
NYSE
9.1% of companies on NYSE
1 company

Andrew Tsai, an analyst at Jefferies Financial Group, currently covers 11 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
10 companies
90.9%
Computer and Technology
1 company
9.1%

Andrew Tsai of Jefferies Financial Group specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
54.5%
MED - GENERIC DRG
1 company
9.1%
MED - OUTP/HM CRE
1 company
9.1%
INTERNET SERVICES
1 company
9.1%
PHARMACEUTICAL PREPARATIONS
1 company
9.1%
MED - DRUGS
1 company
9.1%

Andrew Tsai's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/24/2025Lower Price Target$10.92$35.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
7/18/2025Initiated Coverage$12.35$30.00Buy
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/14/2025Initiated Coverage$46.47$70.00Buy
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/16/2025Lower Price Target$20.65$54.00Buy
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
6/11/2025Boost Price Target$90.82$110.00Buy
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/28/2025Reiterated Rating$2.33Hold
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
5/20/2025Set Price Target$2.02$5.00
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4/7/2025Initiated Coverage$98.86$200.00Buy
KE Holdings Inc. Sponsored ADR stock logo
BEKE
KE
3/19/2025Boost Price Target$22.22$27.00Overweight